The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model

Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies

(2014) David W. Sanders et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transgenic models of Alzheimer's disease: Better utilization of existing models through viral transgenesis

(2013) Thomas L. Platt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Biomarker Modeling of Alzheimer’s Disease

(2013) Clifford R. Jack et al.   NEURON

Animal Models of Alzheimer Disease

(2013) F. M. LaFerla et al.   Cold Spring Harbor Perspectives in Medicine

Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies

(2012) David J. Irwin et al.   BRAIN

Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions

(2012) Masashi Kitazawa et al.   CURRENT PHARMACEUTICAL DESIGN

The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update

(2012) Kelly R Bales   Expert Opinion on Drug Discovery

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

(2012) Thorlakur Jonsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intraneuronal APP, Not Free A  Peptides in 3xTg-AD Mice: Implications for Tau versus A -Mediated Alzheimer Neurodegeneration

(2011) M. J. Winton et al.   JOURNAL OF NEUROSCIENCE

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

(2011) Adam C Naj et al.   NATURE GENETICS

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

(2011) Paul Hollingworth et al.   NATURE GENETICS

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

(2011) Todd E. Golde et al.   NEURON

The acetylation of tau inhibits its function and promotes pathological tau aggregation

(2011) Todd J. Cohen et al.   Nature Communications

The Genetics of Alzheimer Disease: Back to the Future

(2010) Lars Bertram et al.   NEURON

Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

(2009) Jean-Charles Lambert et al.   NATURE GENETICS

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

(2009) Denise Harold et al.   NATURE GENETICS

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

(2009) Guojun Bu   NATURE REVIEWS NEUROSCIENCE

The Role of Apolipoprotein E in Alzheimer's Disease

(2009) Jungsu Kim et al.   NEURON

Blocking A 42 Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between A  and Tau Pathology

(2008) S. Oddo et al.   JOURNAL OF NEUROSCIENCE

The Potential for -Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy

(2008) M.-M. Mocanu et al.   JOURNAL OF NEUROSCIENCE

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

(2008) Lars Bertram et al.   NATURE REVIEWS NEUROSCIENCE

Animal models of Alzheimer's disease and frontotemporal dementia

(2008) Jürgen Götz et al.   NATURE REVIEWS NEUROSCIENCE

Aβ inhibits the proteasome and enhances amyloid and tau accumulation

(2007) Bertrand P. Tseng et al.   NEUROBIOLOGY OF AGING